Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)
Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
There have been growing interest in identifying Parkinson's disease (PD) patients with mild
cognitive impairment (MCI) which is susceptible to progress to PD dementia(PDD). PD-MCI is
known to significantly correlates with low cerebrospinal beta-amyloid 1-42 and 1-40 levels,
in which suggest the existence of something common with Alzheimer's dementia. PDD have showed
more cholinergic deficits than Alzheimer's dementia and responds to donepezil. The
investigators assume that PD-MCI patients also have cholinergic deficits. Donepezil improves
cognition, and seems to be well tolerated and not to worsen parkinsonism in patients with
cognitive impairment. Donepezil produced similar improvements in cognition and behaviour in
DLB and PDD. This supports the hypothesis that the two disorders are closely related
clinically and neurobiologically. Larger scale, placebo controlled clinical trials are needed
to provide an evidence base to guide the clinical use of cholinesterase inhibitors in Lewy
body disease.
It is believed that earlier intervention, later appearance of dementia should be needed to
lower the socioeconomic costs and to improve the quality of life on patients and caregivers.
The investigators anticipate that donepezil may delay the development of dementia in patients
with PD-MCI.